<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160324</url>
  </required_header>
  <id_info>
    <org_study_id>1317</org_study_id>
    <nct_id>NCT05160324</nct_id>
  </id_info>
  <brief_title>T1-T2 Breast Cancer: Comparison Between Removal and Preservation of Axillary Lymph Nodes. (SINODAR ONE)</brief_title>
  <acronym>SINODAR ONE</acronym>
  <official_title>T1-T2 Breast Cancer: Comparison Between Removal and Preservation of Axillary Lymph Nodes in the Presence of Sentinel Lymph Node Metastases. (SINODAR ONE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Humanitas per la Ricerca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Humanitas per la Ricerca</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Italian Multicentric non inferiority two-arm randomized clinical trial to verify that the&#xD;
      experimental treatment (omission of axillary lymph node intervention) in the presence of&#xD;
      sentinel lymph node metastases does not lead to a significant worsening in survival or in the&#xD;
      risk of locoregional recurrence compared to standard treatment (removal of I-II level of&#xD;
      axillary lymph nodes).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description:&#xD;
&#xD;
      The trial is a non-inferiority trial; patients, depending on intra-operative or&#xD;
      post-operative sentinel lymph node assessment, are randomly assigned to one of the two&#xD;
      intervention groups:&#xD;
&#xD;
      group 1: removal of I-II level of axillary lymph nodes (standard treatment). Removal of at&#xD;
      least 10 lymph nodes is recommended.&#xD;
&#xD;
      group 2: no axillary lymph nodes dissection (experimental treatment). Patients for whom&#xD;
      sentinel lymph node cannot be found, will undergo complete dissection of the axillary cavity&#xD;
      as required by international guidelines.&#xD;
&#xD;
      After surgery, according to their bio-pathological profile and to the international&#xD;
      guidelines criteria, patients will be able to receive:&#xD;
&#xD;
        -  no further treatment&#xD;
&#xD;
        -  complementary radiotherapy&#xD;
&#xD;
        -  adjuvant medical therapy (chemo and / or hormone therapy).&#xD;
&#xD;
      Patients will be checked for at least 5 years in the following ways:&#xD;
&#xD;
        -  six-monthly clinical examination for the first 5 years and yearly thereafter&#xD;
&#xD;
        -  mammography + annual breast ultrasound&#xD;
&#xD;
        -  annual axillary ultrasound in cases not subjected to dissection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 14, 2015</start_date>
  <completion_date type="Anticipated">April 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>5 years of follow up after surgery</time_frame>
    <description>Evaluating whether, in women operated for breast cancer (T1-T2) with sentinel lymph node metastases, axillary lymph node conservation is associated with a clinically relevant prognostic worsening (OS). For all the Outcomes Statistical analysis included Kaplan-Meier Product Limit Estimator and the log-rank test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regional Disease Free Survival (RDFS)</measure>
    <time_frame>5 years of follow up after surgery</time_frame>
    <description>Evaluating whether axillary lymph node preservation is associated with a clinically relevant increase of local recurrence rate (ipsilateral axillary and supraclavicular lymph nodes).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free distance survival (DDFS)</measure>
    <time_frame>5 years of follow up after surgery</time_frame>
    <description>Evaluating whether axillary lymph node preservation is associated with a clinically relevant increase in distant recurrence rate.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">889</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Axillary dissection in women with sentinel lymph node metastases.&#xD;
Removal of at least 10 lymph nodes is recommended.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B experimental treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omission of Axillary dissection in women with sentinel lymph node metastases.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Removal of axillary lymph nodes.</intervention_name>
    <description>Axillary dissection in patients with positive sentinel lymph node</description>
    <arm_group_label>A standard treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Preservation of axillary lymph nodes</intervention_name>
    <description>Preservation of axillary lymph nodes in patients with positive sentinel lymph node</description>
    <arm_group_label>B experimental treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 40 ≤75 years old&#xD;
&#xD;
          -  Breast cancer with infiltrating histology&#xD;
&#xD;
          -  Tumor size ≤50 mm (T1 - T2)&#xD;
&#xD;
          -  Clinically and ultrasound node-negative (cN0) breast cancer&#xD;
&#xD;
          -  No distant metastases (M0)&#xD;
&#xD;
          -  No neoadjuvant therapy&#xD;
&#xD;
          -  Negative history of previous infiltrating neoplasm&#xD;
&#xD;
          -  Maximum number of metastatic sentinel lymph nodes: 2&#xD;
&#xD;
          -  Lymph node macro-metastases &gt; 2mm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding in progress&#xD;
&#xD;
          -  Inflammatory breast cancer&#xD;
&#xD;
          -  Breast cancer in situ&#xD;
&#xD;
          -  Synchronous contralateral breast cancer&#xD;
&#xD;
          -  Co-morbidities such as to preclude the possible use of adjuvant therapy&#xD;
&#xD;
          -  Conditions that make it impossible to carry out a regular follow-up&#xD;
&#xD;
          -  Other malignancies within the previous 3 years (except carcinoma in situ of the&#xD;
             uterine cervix, basalioma or squamous cell ca or non-melanoma skin ca)&#xD;
&#xD;
          -  Breast cancer with non-infiltrating or inflammatory histotype&#xD;
&#xD;
          -  Tumor size&gt; 50 mm&#xD;
&#xD;
          -  No sentinel lymph nodes identified&#xD;
&#xD;
          -  No positive sentinel lymph nodes (pN0)&#xD;
&#xD;
          -  Positive sentinel lymph node number &gt; 2&#xD;
&#xD;
          -  Lymph node micro-metastases &lt;= 2&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corrado Tinterri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>axillary dissection, axillary lymph preservation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

